Market Overview
Peptic Ulcer Drugs Market Size was valued at USD 5.07 Billion in 2023. The Global Peptic Ulcer Drugs industry is projected to grow from USD 5.37 Billion in 2024 to USD 7.70 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.18% during the forecast period (2024 - 2032).
Market Highlights
During the forecast period, the global demand for peptic ulcers is projected to rise at a quick rate. Peptic ulcers can be caused by lifestyle-related causes such as aerated beverages, alcoholism, fatty food intake, and stress. This is a significant force that propels the worldwide demand for peptic ulcers. Peptic ulcers in the geriatric community can cause serious morbidity. Therefore, the growth of this demographic is a key factor expected during the forecast period to drive the demand. In addition , the rise in the patient population and the increase in opioid intake, such as aspirin , ibuprofen and other inflammatory medications, are the other reasons that are likely to increase the global demand for peptic ulcers. Factors such as the rising smoking prevalence are also anticipated to encourage the widening of the global demand for peptic ulcer medications over the projected period.
Because of the current COVID-19 pandemic-an acute respiratory distress syndrome triggered by the novel coronavirus-the most unparalleled institutional and economic problems have arisen. Furthermore, for the production and commercialization of appropriate treatment options for this new COVID-19 pathogen, a substantial amount of time is needed. It is projected that these joint infection transmission and management issues will hinder the diagnosis and treatment of GI-disease in the coming quarters of 2020 and 2021. Owing to the prioritisation of COVID-19 care, decreased doctor and hospital visits for non-essential health conditions would hinder market development. Due to the availability of COVID-19 vaccines, the market for peptic ulcer medications is expected to return to pre-pandemic market demand in 2021. This will be mirrored in the rebound from the COVID-19 pandemic in developing and emerging economies. In addition, local officials are prioritising healthcare services to meet the complexities of COVID-19, which is also likely to slow down the short-term growth of the demand for peptic ulcer medications.
Nevertheless, the adverse effects of peptic ulcer medications, low pipeline efficiency, and changes in drug pricing policies are factors that are likely to impede the development of the global peptic ulcer drug industry in the coming years.
Competitive Dashboard
Daiichi Sankyo Company Limited,
Novartis AG,
Acetelion Ltd.,
Sanofi S.A.,
Boehringer Ingelheim,
Astra Zeneca plc,
Takeda Pharmaceuticals Company Limited,
Ranbaxy Laboratories Limited, Inc.,
Pfizer Inc.,
Eumedica Pharmaceuticals, and
Helicure AB,
are some of the key players operating in the peptic ulcer drugs market.
Segmental Analysis
The global peptic ulcer drugs market has been segmented on the basis of pharmacological class into proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others.
The market is segmented by clinical application into gastric ulcers, duodenal ulcer, and esophageal ulcer.
Regional Overview
Geographically, the global peptic ulcer market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
It is estimated that North America will lead the global demand for peptic ulcers, accounting for the highest share over the expected period. A increase in non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and the understanding of peptic ulcer treatment options are factors that are expected to boost the growth demand for peptic ulcer drugs in the North American region. North America 's market rise is due to an rise in the prevalence of stomach cancer in the country.
The second largest share of the demand for peptic ulcer drugs in Europe is partly due to the simple availability of effective treatment alternatives for peptic ulcers in the country.
During the forecast period, the Asia Pacific market is projected to develop at a higher growth rate. Because of the large population, growth in health consciousness and high prevalence of lifestyle-related diseases, stomach infections caused by H, it is the most lucrative market. Pylori, as well as cancer.
Related Reports-
Patient Engagement Solutions market
Drug Device Combination market
Comments (0)